Comparative Assessment of Inclisiran on Top of Standard of Care Versus Standard of Care Alone for LDL-C Evaluation in Acute Coronary Syndrome Patients in Saudi Arabia

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 300 participants.

Also called NCT07684469

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 300 participants (planned count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT07684469
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07684469. Randomized; no masking; primary purpose treatment. Start 2026-10-31 (anticipated); primary completion 2028-02-29 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comparative Assessment of Inclisiran on Top of Standard of Care Versus Standard of Care Alone for LDL-C Evaluation in Acute Coronary Syndrome Patients in Saudi Arabia
Condition
Acute Coronary Syndrome
Intervention (Drug)
inclisiran
Intervention (Drug)
SOC
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct07684469
Content hash
8d4436591336ea0dea2d0d376035455823bae47ce6ff2dcf02b88843a44dfc88